Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other EventsItem 8.01.Other Events.
On September28, 2017, Agile Therapeutics,Inc. (“Agile”) a women’s healthcare company, announced that an abstract based on the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch (AG200-15) has been selected for a poster presentation during the North American Forum on Family Planning Annual Meeting being held October14th— 16th, 2017 in Atlanta, GA. The abstract, titled “Bleeding And Spotting Results From The SECURE Trial: A Phase 3 Study Of The AG200-15 Investigational Transdermal Contraceptive Patch,” will be available in the October2017 issue of Contraception or online at http://www.contraceptionjournal.org.
Copies of Agile’s press release and abstract are attached hereto as Exhibit99.1 and 99.2, respectively, and are hereby incorporated by reference herein.
Item 8.01. Financial Statements and Exhibits.
(d) Exhibits.
AGILE THERAPEUTICS INC ExhibitEX-99.1 2 a17-22636_1ex99d1.htm EX-99.1 Exhibit 99.1 Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting PRINCETON,…To view the full exhibit click here
About Agile Therapeutics,Inc. (NASDAQ:AGRX)
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.